Gritstone Oncology shares nearly quadruple after receiving NIH support on vaccine trial

Gritstone Oncology CEO Andrew Allen said the drugmaker hopes their potential coronavirus vaccine could help mitigate the spread of Covid-19 variants.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.